Effects of concomitant administration of strong inhibitors of BCRP and P- gp transporters on the pharmacokinetics (PK) of rimegepant in healthy subjects
Latest Information Update: 22 Jul 2022
At a glance
- Drugs Rimegepant (Primary) ; Ciclosporin; Quinidine
- Indications Migraine; Plaque psoriasis; Rhinosinusitis; Temporomandibular joint dysfunction syndrome; Trigeminal neuralgia
- Focus Pharmacokinetics
- 01 Jul 2022 Results assessing the the effects of concomitant administration of strong inhibitors of these transporters on the pharmacokinetics of rimegepant in healthy subjects published in the Clinical Pharmacology in Drug Development
- 26 Apr 2022 Results assessing the the effect of strong inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) on the pharmacokinetics (PK) of rimegepant in healthy adults presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 01 Aug 2021 New trial record